Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No need to suffer heartburn after a heart attack

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Although proton pump inhibitors do have a negative influence on the antiplatelet effects of clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) and prasugrel (Lilly/Daiichi Sankyo's Effient), the antacids don't appear to interfere with the clinical outcome for patients, according to an analysis of data from the TIMI-44 and TIMI-38 trials presented Sept. 1 at the European Society of Cardiology congress. The antacids are thought to inhibit the conversion of the thienopyridine class drugs into active form in the body, and the drug-drug interaction has sparked safety warnings from both FDA and EMEA. Professional guidelines, however, still recommend administering PPIs with the antiplatelet drugs to help reduce the risk of gastrointestinal bleeding. AstraZeneca's experimental antiplatelet drug Brilinta (ticagrelor), for which positive Phase III data was presented at ESC, may offer a solution to the interaction dilemma if it is approved as anticipated in 2010. Ticagrelor has a different mechanism of action from clopidogrel or prasugrel; it is an active compound that does not require bioactivation (1"The Pink Sheet," Sept. 7, 2009)

You may also be interested in...



AstraZeneca's Ticagrelor Brilliant At ECS Congress; Will It Outshine Effient?

The comparator in AstraZeneca's PLATO trial for its antiplatelet candidate Brilinta (ticagrelor) was clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) but the real test for the product, should it reach the market, may be against Eli Lilly/Daiichi Sankyo's recently approved Effient (prasugrel)

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research

Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.

Topics

UsernamePublicRestriction

Register

PS004239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel